{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:41Z","timestamp":1791245201030,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    This paper describes the peculiarities of the plasma-derived medicinal product (PDMP) market and illustrates the results of a review of the literature on policies aimed at counteracting the shortage of PDMPs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Characteristics of PDMPs:<\/jats:bold>\n                    Plasma is primarily used for the industrial production of blood products (80%). The demand for PDMPs, particularly immunoglobulins (IGs), is increasing. However, the production of PDMPs is complex, long (7\n                    <jats:bold>\u2013<\/jats:bold>\n                    12\u00a0months), and expensive, accounting, according to US estimates, for 57% of the total costs of PDMPs compared to 14% for small molecules.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PDMP market:<\/jats:bold>\n                    Unexpected increases in clinical need cannot be addressed in the short term. Once the demand for some diseases is satisfied, the collection and fractionation of plasma will only be used to supply some specific patients. Hence, the full weight of the marginal costs, which remain constant, are borne by a few products. According to last liter economics, the industry stops producing when the marginal revenue equals the marginal cost, thereby reducing the convenience of producing the most commonly used PDMPs (albumin and IG). The imbalance between the demand and supply of PDMPs was exacerbated by the COVID-19 pandemic, which further increased the cost of plasma collection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Shortage issue and possible solutions:<\/jats:bold>\n                    Policies to counteract this imbalance have also been discussed. If the demand is inappropriate, it should be reduced. If the demand is appropriate and supply cannot be increased, the demand should be prioritized for patients for whom PDMPs are the only available treatment. If the shortage depends on insufficient supply and technical and allocative efficiency, both production and supply should be improved, together with incentives for all stakeholders involved in the PDMP market to increase the sustainability of production\/supply. The paper is focused on this second issue, that is supply-driven unbalance.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1375891","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:45:36Z","timestamp":1714956336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy"],"prefix":"10.3389","volume":"15","author":[{"given":"Matteo","family":"Bolcato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Jommi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"B1","unstructured":"Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilit\u00e0 e prezzo di un medicinale2020"},{"key":"B2","unstructured":"Documento di indirizzo AIFA e CNS sull\u2019uso delle immunoglobuline umane in condizioni di carenza2022"},{"key":"B3","unstructured":"Actualit\u00e9 - Utilisation des immunoglobulines humaines polyvalentes (Ig) dans un contexte de fortes tensions d\u2019approvisionnement: diffusion d\u2019une note d\u2019information relative \u00e0 la hi\u00e9rarchisation des indications2018"},{"key":"B4","article-title":"Calo di donazioni di plasma, a rischio la produzione di plasmaderivati","author":"Bernini","year":"2021","journal-title":"MakingPharmacist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tracli.2017.06.001","article-title":"Determinants of plasma donation: a review of the literature","volume":"24","author":"Beurel","year":"2017","journal-title":"Transfus. Clinique Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.transci.2019.03.022","article-title":"Efficacy of a strict surveillance policy towards inappropriateness of plasma transfusion","volume":"58","author":"Beverina","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"102779","DOI":"10.1016\/j.transci.2020.102779","article-title":"Patient blood management: the best approach to transfusion medicine risk management","volume":"59","author":"Bolcato","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1215\/03616878-27-6-977","article-title":"Responding to the immunoglobulin shortage: a case study","volume":"27","author":"Boulis","year":"2002","journal-title":"J. Health Polit. Policy Law"},{"key":"B9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.tracli.2020.12.005","article-title":"Review of indications for immunoglobulin (IG) use: narrowing the gap between supply and demand","volume":"28","author":"Brand","year":"2021","journal-title":"Transfus. Clin. Biol."},{"key":"B10","article-title":"As COVID-19 cases rise in U.S., precious plasma donations lag","author":"Brown","year":"2020","journal-title":"Reuters"},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","article-title":"Social\/economic costs and quality of life in patients with haemophilia in Europe","volume":"17","author":"Cavazza","year":"2016","journal-title":"Eur. J. Health Econ."},{"key":"B12","unstructured":"The national plan for management of shortages of immunoglobulin products (ig) \u2013 interim guidance2020"},{"key":"B13","article-title":"Rapporto ISTISAN 23\/6 EN - demand for plasma-derived medicinal products in Italy. 2021","author":"Candura","year":"2023","journal-title":"ISS"},{"key":"B14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1160\/TH16-04-0266","article-title":"Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis","volume":"116","author":"Chai-Adisaksopha","year":"2016","journal-title":"Thromb. Haemost."},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12871-020-0945-x","article-title":"Liver transplantation in Jehovah\u2019s witnesses: 13 consecutive cases at a single institution","volume":"20","author":"Costanzo","year":"2020","journal-title":"BMC Anesthesiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood.2021015370","article-title":"Shortage of plasma-derived products: a looming crisis?","volume":"139","author":"Covington","year":"2022","journal-title":"Blood"},{"key":"B17","first-page":"2","article-title":"Plasma economics and the rising cost of immunoglobulin","year":"2022","journal-title":"Rare Revolut. 021(S)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/vox.12792","article-title":"Contract plasma fractionation: strategies for self sufficiency of plasma derived medicinal products from voluntary non remunerated donations. Abstract of 29th Regional Congress of the ISBT","volume":"114","author":"De Angelis","year":"2019","journal-title":"Vox Sang."},{"key":"B19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000496750","article-title":"Trends in plasma toll fractionation for self sufficiency of plasma-derived medicinal products in Italy","volume":"46","author":"De Angelis","year":"2019","journal-title":"Transfus. Med. Hemother"},{"key":"B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1751-2824.2010.01373.x","article-title":"Donor management: DOMAINE \u2013 the European perspective","volume":"5","author":"De Kort","year":"2010","journal-title":"ISBT Sci. Ser."},{"key":"B21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7861\/clinmedicine.13-2-197","article-title":"Uses and abuses of fresh-frozen plasma for the prophylaxis of bleeding","volume":"13","author":"Desborough","year":"2013","journal-title":"Clin. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.tracli.2020.12.004","article-title":"The interphase between immunoglobulin, the plasma industry and the public health, managing a finite resource","volume":"28","author":"Farrugia","year":"2021","journal-title":"Transfus. Clinique Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2450\/2019.0265-19","article-title":"The growing importance of achieving national self-sufficiency in immunoglobulin in Italy. The emergence of a national imperative","volume":"17","author":"Farrugia","year":"2019","journal-title":"Blood Transfus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1365-3148.2001.00288.x","article-title":"Intravenous immunoglobulin: regulatory perspectives on use and supply","volume":"11","author":"Farrugia","year":"2001","journal-title":"Transfus. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.biologicals.2017.02.007","article-title":"The dynamics of contract plasma fractionation","volume":"46","author":"Farrugia","year":"2017","journal-title":"Biologicals"},{"key":"B26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/voxs.12100","article-title":"Self-sufficiency in PDMP based on VNRBD - an achievable goal?","volume":"9","author":"Flanagan","year":"2014","journal-title":"VOXS"},{"key":"B27","unstructured":"Key economic and value considerations in the U.S. market for plasma protein therapies\n            GrabowskiH.\n            ManningR.\n          2018"},{"key":"B28","doi-asserted-by":"publisher","first-page":"s138","DOI":"10.2450\/2013.020s","article-title":"Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing","author":"Grazzini","year":"2013","journal-title":"Blood Transfus."},{"key":"B29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.15167","article-title":"British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding","volume":"181","author":"Green","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B30","unstructured":"The impact of plasma derived therapies in Europe. The health and economic case for ensuring sustainable supply\n            Haanper\u00e4T.\n            JervelundC.\n            Siersb\u00e6kN.\n          2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1111\/trf.16078","article-title":"Supply and demand for plasma-derived medicinal products - a critical reassessment amid the COVID-19 pandemic","volume":"60","author":"Hartmann","year":"2020","journal-title":"Transfusion"},{"key":"B32","unstructured":"Immunoglobulin therapies in the US: how they are used, a roundtable report2022"},{"key":"B33","article-title":"Il futuro demografico del paese","year":"2018","journal-title":"Previs. Reg. della Pop. Resid. al"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clinthera.2019.11.006","article-title":"Implementation of value-based pricing for medicines","volume":"42","author":"Jommi","year":"2020","journal-title":"Clin. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","article-title":"Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe","volume":"5","author":"Kerr","year":"2014","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","article-title":"Evidence for the use of intravenous immunoglobulins\u2014a review of the literature","volume":"38","author":"Kivity","year":"2010","journal-title":"Clin. Rev. Allerg. Immunol."},{"key":"B37","unstructured":"Appropriate use of immunoglobulins\n            KluszczynskiT.\n            Barbosa EitelN.\n          2022"},{"key":"B38","unstructured":"Key economic and value considerations for plasma-derived medicinal products (PDMPs) in Europe\n            KluszczynskiT.\n            RohrS.\n            ErnstR.\n          2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"s13","DOI":"10.2450\/2013.004s","article-title":"Plasma-derived medicinal products in Italy: information sources and flows","author":"Lanzoni","year":"2013","journal-title":"Blood Transfus."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/trf.14006","article-title":"Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals","volume":"57","author":"Leahy","year":"2017","journal-title":"Transfusion"},{"key":"B41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2450\/2009.0005-09","article-title":"Recommendations for the transfusion of plasma and platelets","volume":"7","author":"Liumbruno","year":"2009","journal-title":"Blood Transfus."},{"key":"B42","first-page":"106","volume-title":"Business briefs. IBPN international blood\/plasma news","year":"2020"},{"key":"B43","unstructured":"DECRETO 2 novembre 2015. Disposizioni relative ai requisiti di qualita\u2019 e sicurezza del sangue e degli emocomponenti. (15A09709) (GU Serie Generale n.300 del 28-12-2015 - Suppl. Ordinario n. 69)2015"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","article-title":"Global immunoglobulin supply: steaming towards the iceberg?","volume":"20","author":"Prevot","year":"2020","journal-title":"Curr. Opin. Allergy & Clin. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13223-022-00662-6","article-title":"Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network","volume":"18","author":"Quinn","year":"2022","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1537-2995.2010.02632.x","article-title":"Evidence-based practice guidelines for plasma transfusion: EVIDENCE-BASED GUIDELINES FOR PLASMA USE","volume":"50","author":"Roback","year":"2010","journal-title":"Transfusion"},{"key":"B48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0955-3886(00)00056-4","article-title":"The supply of blood products in 10 different systems or countries","volume":"22","author":"Rock","year":"2000","journal-title":"Transfus. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1213\/ANE.0000000000005873","article-title":"A global definition of patient blood management","volume":"135","author":"Shander","year":"2022","journal-title":"Anesth. Analgesia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/CCM.0000000000001599","article-title":"Outcomes of protocol-driven care of critically ill severely anemic patients for whom blood transfusion is not an option","volume":"44","author":"Shander","year":"2016","journal-title":"Crit. Care Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000528959","article-title":"Challenges for plasma-derived medicinal products","volume":"50","author":"Strengers","year":"2023","journal-title":"Transfus. Med. Hemother"},{"key":"B52","unstructured":"Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002\/98\/EC and 2004\/23\/EC2022"},{"key":"B53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","article-title":"How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries","volume":"15","author":"Vogler","year":"2017","journal-title":"Appl. Health Econ. Health Policy"},{"key":"B54","unstructured":"Intravenous immunoglobulin use2018"},{"key":"B55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1423-0410.2012.01630.x","article-title":"Expert Consensus Statement on achieving self-sufficiency in safe blood and blood products, based on voluntary non-remunerated blood donation (VNRBD)*: self-sufficiency in blood and blood products based on VNRBD","volume":"103","year":"2012","journal-title":"Vox Sang."},{"key":"B56","unstructured":"WHO model list of essential medicines - 22nd list, 20212021"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1375891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:45:48Z","timestamp":1714956348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1375891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":56,"alternative-id":["10.3389\/fphar.2024.1375891"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1375891","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"article-number":"1375891"}}